Anika Therapeutics (ANIK) Net Income towards Common Stockholders Growth (3y) (2013 - 2025)
Anika Therapeutics (ANIK) Net Income towards Common Stockholders Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 47.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.06% |
| Sep 30, 2025 | 30.12% |
| Jun 30, 2025 | 30.81% |
| Mar 31, 2025 | 31.98% |
| Dec 31, 2024 | -81.63% |
| Sep 30, 2024 | -275.29% |
| Jun 30, 2024 | -27.85% |
| Mar 31, 2024 | -42.63% |
| Dec 31, 2023 | 44.72% |
| Sep 30, 2023 | -0.66% |
| Jun 30, 2023 | 29.14% |
| Mar 31, 2023 | -55.87% |
| Dec 31, 2022 | 17.36% |
| Sep 30, 2022 | -34.85% |
| Jun 30, 2022 | -32.03% |
| Mar 31, 2022 | -38.30% |
| Dec 31, 2021 | -33.61% |
| Sep 30, 2021 | -58.28% |
| Jun 30, 2021 | -13.51% |
| Mar 31, 2021 | 34.34% |